Is NVS or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media refer more to NVS or NVO?

In the previous week, Novo Nordisk A/S had 43 more articles in the media than Novartis. MarketBeat recorded 49 mentions for Novo Nordisk A/S and 6 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.83 beat Novartis' score of 0.62 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 32 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer AZN or NVO?

In the previous week, Novo Nordisk A/S had 41 more articles in the media than Astrazeneca. MarketBeat recorded 49 mentions for Novo Nordisk A/S and 8 mentions for Astrazeneca. Novo Nordisk A/S's average media sentiment score of 0.83 beat Astrazeneca's score of 0.60 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 32 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive

Which has stronger earnings & valuation, NVO or GSK?

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.12 $15.51B $4.26 10.14 GSK $43.07B 2.39 $7.54B $3.85 13.18

Is NVO or GSK more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% GSK 17.82% 44.28% 11.49%

Does the media prefer NVO or GSK?

In the previous week, Novo Nordisk A/S had 38 more articles in the media than GSK. MarketBeat recorded 49 mentions for Novo Nordisk A/S and 11 mentions for GSK. GSK's average media sentiment score of 0.85 beat Novo Nordisk A/S's score of 0.83 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 32 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive GSK 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, SNY or NVO?

Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.08 $8.84B $3.58 11.84 Novo Nordisk A/S $46.80B 4.12 $15.51B $4.26 10.14

Is SNY or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media refer more to SNY or NVO?

In the previous week, Novo Nordisk A/S had 44 more articles in the media than Sanofi. MarketBeat recorded 49 mentions for Novo Nordisk A/S and 5 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 0.83 beat Sanofi's score of 0.47 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Novo Nordisk A/S 32 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive

Which has preferable valuation & earnings, NVO or ARGX?

Novo Nordisk A/S has higher revenue and earnings than argenex. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.12 $15.51B $4.26 10.14 argenex $4.25B 12.85 $1.29B $22.46 39.08

Is NVO or ARGX more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to argenex's net margin of 31.31%. Novo Nordisk A/S's return on equity of 63.31% beat argenex's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% argenex 31.31% 44.37% 37.55%

Does the media prefer NVO or ARGX?

In the previous week, Novo Nordisk A/S had 45 more articles in the media than argenex. MarketBeat recorded 49 mentions for Novo Nordisk A/S and 4 mentions for argenex. Novo Nordisk A/S's average media sentiment score of 0.83 beat argenex's score of 0.72 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 32 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive argenex 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Novo Nordisk A/S (NVO) Competitors

$43.20 -0.32 (-0.74%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$43.09 -0.11 (-0.25%)

As of 06/18/2026 07:59 PM Eastern

Compare

NVO vs. NVS, AZN, GSK, SNY, and ARGX

Should you buy Novo Nordisk A/S stock or one of its competitors? MarketBeat compares Novo Nordisk A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novo Nordisk A/S include Novartis (NVS), Astrazeneca (AZN), GSK (GSK), Sanofi (SNY), and argenex (ARGX). These companies are all part of the "pharmaceutical products" industry.

How does Novo Nordisk A/S compare to Novartis?

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, Novo Nordisk A/S had 43 more articles in the media than Novartis. MarketBeat recorded 49 mentions for Novo Nordisk A/S and 6 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.83 beat Novartis' score of 0.62 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	32 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

13.1% of Novartis shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 4.1%. Novartis pays out 44.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novartis has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Novartis presently has a consensus price target of $141.20, indicating a potential downside of 4.06%. Novo Nordisk A/S has a consensus price target of $65.56, indicating a potential upside of 51.77%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.15	$13.98B	$6.98	21.08
Novo Nordisk A/S	$46.80B	4.12	$15.51B	$4.26	10.14

Summary

Novo Nordisk A/S beats Novartis on 11 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novo Nordisk A/S (NYSE:NVO) are both large-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Astrazeneca has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Astrazeneca presently has a consensus price target of $205.33, suggesting a potential upside of 17.42%. Novo Nordisk A/S has a consensus price target of $65.56, suggesting a potential upside of 51.77%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Novo Nordisk A/S has a net margin of 37.23% compared to Astrazeneca's net margin of 17.19%. Novo Nordisk A/S's return on equity of 63.31% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.5%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 4.1%. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has lower revenue, but higher earnings than Astrazeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.62	$10.23B	$6.66	26.26
Novo Nordisk A/S	$46.80B	4.12	$15.51B	$4.26	10.14

In the previous week, Novo Nordisk A/S had 41 more articles in the media than Astrazeneca. MarketBeat recorded 49 mentions for Novo Nordisk A/S and 8 mentions for Astrazeneca. Novo Nordisk A/S's average media sentiment score of 0.83 beat Astrazeneca's score of 0.60 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	32 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Novo Nordisk A/S beats Astrazeneca on 11 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to GSK?

Novo Nordisk A/S (NYSE:NVO) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 4.1%. GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.6%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. GSK pays out 47.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Novo Nordisk A/S had 38 more articles in the media than GSK. MarketBeat recorded 49 mentions for Novo Nordisk A/S and 11 mentions for GSK. GSK's average media sentiment score of 0.85 beat Novo Nordisk A/S's score of 0.83 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	32 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
GSK	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.12	$15.51B	$4.26	10.14
GSK	$43.07B	2.39	$7.54B	$3.85	13.18

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Novo Nordisk A/S has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

Novo Nordisk A/S presently has a consensus target price of $65.56, indicating a potential upside of 51.77%. GSK has a consensus target price of $53.00, indicating a potential upside of 4.41%. Given Novo Nordisk A/S's stronger consensus rating and higher probable upside, equities analysts clearly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
GSK	3 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
GSK	17.82%	44.28%	11.49%

Summary

Novo Nordisk A/S beats GSK on 14 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Sanofi?

Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.08	$8.84B	$3.58	11.84
Novo Nordisk A/S	$46.80B	4.12	$15.51B	$4.26	10.14

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.2%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 4.1%. Sanofi pays out 49.2% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Sanofi presently has a consensus price target of $51.00, suggesting a potential upside of 20.34%. Novo Nordisk A/S has a consensus price target of $65.56, suggesting a potential upside of 51.77%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Sanofi has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Novo Nordisk A/S	37.23%	63.31%	22.19%

In the previous week, Novo Nordisk A/S had 44 more articles in the media than Sanofi. MarketBeat recorded 49 mentions for Novo Nordisk A/S and 5 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 0.83 beat Sanofi's score of 0.47 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novo Nordisk A/S	32 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Novo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Novo Nordisk A/S compare to argenex?

Novo Nordisk A/S (NYSE:NVO) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Novo Nordisk A/S has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Novo Nordisk A/S has a net margin of 37.23% compared to argenex's net margin of 31.31%. Novo Nordisk A/S's return on equity of 63.31% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
argenex	31.31%	44.37%	37.55%

Novo Nordisk A/S currently has a consensus price target of $65.56, suggesting a potential upside of 51.77%. argenex has a consensus price target of $1,019.50, suggesting a potential upside of 16.15%. Given Novo Nordisk A/S's higher probable upside, research analysts plainly believe Novo Nordisk A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, Novo Nordisk A/S had 45 more articles in the media than argenex. MarketBeat recorded 49 mentions for Novo Nordisk A/S and 4 mentions for argenex. Novo Nordisk A/S's average media sentiment score of 0.83 beat argenex's score of 0.72 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	32 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
argenex	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S has higher revenue and earnings than argenex. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.12	$15.51B	$4.26	10.14
argenex	$4.25B	12.85	$1.29B	$22.46	39.08

Summary

argenex beats Novo Nordisk A/S on 9 of the 17 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVO vs. The Competition

Export

Metric	Novo Nordisk A/S	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$194.32B	$308.09B	$6.66B	$23.14B
Dividend Yield	4.02%	2.80%	2.68%	4.07%
P/E Ratio	10.14	27.04	24.46	31.62
Price / Sales	4.12	4.99	577.04	22.79
Price / Cash	9.28	13.13	44.20	24.08
Price / Book	6.57	7.72	10.70	4.68
Net Income	$15.51B	$11.61B	$3.57B	$1.08B
7 Day Performance	-1.60%	-3.12%	0.68%	-0.82%
1 Month Performance	-2.35%	-0.49%	3.92%	3.11%
1 Year Performance	-41.64%	18.05%	28.51%	24.65%

Novo Nordisk A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVO Novo Nordisk A/S	4.2174 of 5 stars	$43.20 -0.7%	$65.56 +51.8%	-41.6%	$194.32B	$46.80B	10.14	69,505	Trending News
NVS Novartis	2.5918 of 5 stars	$152.31 +0.9%	$141.20 -7.3%	+26.9%	$290.33B	$56.58B	21.80	75,267
AZN Astrazeneca	4.5773 of 5 stars	$179.50 +0.4%	$205.33 +14.4%	+23.6%	$278.44B	$58.74B	26.96	96,100
GSK GSK	3.4938 of 5 stars	$52.57 +0.7%	$53.00 +0.8%	+31.3%	$106.30B	$32.78B	13.64	66,841	Dividend Cut Options Volume
SNY Sanofi	4.3087 of 5 stars	$43.48 -1.3%	$51.00 +17.3%	-11.0%	$105.42B	$49.35B	12.15	74,846

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVO) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Competitors

NVO vs. NVS, AZN, GSK, SNY, and ARGX

How does Novo Nordisk A/S compare to Novartis?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Summary

How does Novo Nordisk A/S compare to GSK?

Summary

How does Novo Nordisk A/S compare to Sanofi?

Summary

How does Novo Nordisk A/S compare to argenex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Competitors

NVO vs. NVS, AZN, GSK, SNY, and ARGX

How does Novo Nordisk A/S compare to Novartis?

Does the media refer more to NVS or NVO?

Do institutionals & insiders believe in NVS or NVO?

Is NVS or NVO a better dividend stock?

Which has more volatility & risk, NVS or NVO?

Is NVS or NVO more profitable?

Do analysts prefer NVS or NVO?

Which has better earnings and valuation, NVS or NVO?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Do institutionals & insiders have more ownership in AZN or NVO?

Which has more volatility & risk, AZN or NVO?

Do analysts recommend AZN or NVO?

Is AZN or NVO more profitable?

Is AZN or NVO a better dividend stock?

Which has stronger earnings & valuation, AZN or NVO?

Does the media prefer AZN or NVO?

Summary

How does Novo Nordisk A/S compare to GSK?

Is NVO or GSK a better dividend stock?

Does the media prefer NVO or GSK?

Which has stronger earnings & valuation, NVO or GSK?

Do institutionals and insiders believe in NVO or GSK?

Which has more volatility and risk, NVO or GSK?

Do analysts recommend NVO or GSK?

Is NVO or GSK more profitable?

Summary

How does Novo Nordisk A/S compare to Sanofi?

Which has stronger earnings and valuation, SNY or NVO?

Is SNY or NVO a better dividend stock?

Do analysts recommend SNY or NVO?

Which has more risk and volatility, SNY or NVO?

Do insiders and institutionals hold more shares of SNY or NVO?

Is SNY or NVO more profitable?

Does the media refer more to SNY or NVO?

Summary

How does Novo Nordisk A/S compare to argenex?

Which has more risk and volatility, NVO or ARGX?

Do institutionals & insiders hold more shares of NVO or ARGX?

Is NVO or ARGX more profitable?

Do analysts rate NVO or ARGX?

Does the media prefer NVO or ARGX?

Which has preferable valuation & earnings, NVO or ARGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools